COVID-19 Monoclonal Antibody Administration Linked to Drop in Blood Pressure: A Retrospective Cohort Study.

Autor: CarlLee S; College of Medicine, University of Arkansas for Medical Sciences, Fayetteville, Arkansas, USA., Diaz-Cruz A; College of Medicine, University of Arkansas for Medical Sciences, Fayetteville, Arkansas, USA., Brand R; College of Medicine, University of Arkansas for Medical Sciences, Fayetteville, Arkansas, USA., Reece S; College of Medicine, University of Arkansas for Medical Sciences, Fayetteville, Arkansas, USA., Robinson S; Department of Mathematical Sciences, University of Arkansas, Fayetteville, Arkansas, USA., West J; Department of Mathematical Sciences, University of Arkansas, Fayetteville, Arkansas, USA., Dare RK; Division of Infectious Diseases, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA., Jensen H; College of Medicine, University of Arkansas for Medical Sciences, Fayetteville, Arkansas, USA.
Jazyk: angličtina
Zdroj: Monoclonal antibodies in immunodiagnosis and immunotherapy [Monoclon Antib Immunodiagn Immunother] 2023 Apr; Vol. 42 (2), pp. 65-67. Date of Electronic Publication: 2023 Feb 14.
DOI: 10.1089/mab.2022.0038
Abstrakt: This study reports on hemodynamic changes observed during monoclonal antibody (mAb) administration for patients with severe acute respiratory distress syndrome-coronavirus-2. Findings from this study may have implications for patient safety. Hemodynamic data from 705 patients who received subcutaneous or intravenous mAb therapy during February 1, 2021-September 30, 2021 in clinics in Arkansas, USA were reviewed. Descriptive statistics and paired t -tests were used to assess blood pressure before and after treatment. Results showed 386 (54.7%) patients experienced a drop in systolic blood pressure (SBP) or diastolic blood pressure (DBP) >5 mmHg. The average drop in SBP was 9.2 mmHg for those patients. Two hundred and eighty-one (39.9%) patients experienced a drop in SBP of >10 mmHg with an average drop in SBP of 12.0 mmHg. The Emergency Use Authorization for mAb does not list hypotension as a contraindication for treatment. Our findings suggest mAb therapy should be administered in an environment where vitals are monitored.
Databáze: MEDLINE
Externí odkaz: